What is HC Wainwright's Forecast for DWTX FY2029 Earnings?

Key Points

• HC Wainwright lowered its FY2029 EPS forecast for Dogwood Therapeutics to $0.52 from $0.55, while maintaining a “Buy” rating and $12 price target. The firm projects FY2030 EPS of $1.29.
• Dogwood reported a second-quarter loss of $0.34 per share, missing the $0.14 consensus estimate by $0.20. Analyst sentiment remains mixed, resulting in an overall “Hold” consensus.
• DWTX opened at $2.15, with a market capitalization of approximately $72.3 million and a 12-month trading range of $1.28 to $9.50. Institutional investors and hedge funds own about 9.05% of the stock.

Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) - HC Wainwright cut their FY2029 earnings estimates for Dogwood Therapeutics in a research report issued on Friday, August 14th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of $0.52 per share for the year, down from their previous forecast of $0.55. HC Wainwright has a "Buy" rating and a $12.00 price objective on the stock. The consensus estimate for Dogwood Therapeutics' current full-year earnings is ($0.55) per share. HC Wainwright also issued estimates for Dogwood Therapeutics' FY2030 earnings at $1.29 EPS.

Dogwood Therapeutics (NASDAQ:DWTX - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20).

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Dogwood Therapeutics in a report on Friday, July 24th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Dogwood Therapeutics has an average rating of "Hold" and a consensus price target of $12.00.

Dogwood Therapeutics Stock Performance

NASDAQ:DWTX opened at $2.15 on Monday. The firm's fifty day simple moving average is $1.57 and its 200 day simple moving average is $2.04. Dogwood Therapeutics has a twelve month low of $1.28 and a twelve month high of $9.50. The firm has a market capitalization of $72.30 million, a price-to-earnings ratio of -0.24 and a beta of 1.71.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new position in Dogwood Therapeutics stock. Marshall Wace LLP acquired a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 11,655 shares of the company's stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent SEC filing. 9.05% of the stock is owned by institutional investors and hedge funds.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood's lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source